The Financial Burden of Public Health Responses to Hepatitis A Cases Among Food Handlers, 2012-2014

Public Health Rep. 2017 Jul/Aug;132(4):443-447. doi: 10.1177/0033354917710947. Epub 2017 Jun 13.

Abstract

When food handlers become ill with hepatitis A virus (HAV) infection, state and local health departments must assess the risk of HAV transmission through prepared food and recommend or provide postexposure prophylaxis (PEP) for those at risk for HAV infection. Providing PEP (eg, hepatitis A [HepA] vaccine or immunoglobulin), however, is costly. To describe the burden of these responses on state and local health departments, we determined the number of public health responses to HAV infections among food handlers by reviewing public internet sources of media articles. We then contacted each health department to collect data on whether PEP was recommended to food handlers or restaurant patrons, the number of PEP doses given, the number of HepA vaccine or immunoglobulin doses given as PEP, and the mean number of health department person-hours required for the response. Of 32 public health responses identified from Twitter, HealthMap, and Google alerts from January 1, 2012, to December 31, 2014, a total of 27 (84%) recommended PEP for other food handlers or restaurant patrons or both. Per public health response, the mean cost per dose of the HepA vaccine or immunoglobulin was $34 139; the mean personnel cost per response was $7329; and the total mean cost of each response was $41 468. PEP is expensive. Less aggressive approaches to PEP, such as limiting PEP to fellow food handlers in nonoutbreak situations, should be considered in the postvaccination era. HepA vaccine for PEP provides long-term immunity and can be used when immunoglobulin is unavailable or cannot be administered within 14 days of exposure to HAV.

Keywords: food handler; hepatitis A vaccine; hepatitis A virus; postexposure prophylaxis.

MeSH terms

  • Disease Outbreaks / economics*
  • Food Handling / statistics & numerical data*
  • Hepatitis A / prevention & control
  • Hepatitis A Vaccines / economics*
  • Hepatitis A Vaccines / therapeutic use
  • Humans
  • Post-Exposure Prophylaxis / statistics & numerical data
  • Public Health / methods*
  • United States

Substances

  • Hepatitis A Vaccines